Eddie Cliff
@eddiecliff.bsky.social
haematology registrar PMCC & RMH | research affiliate, PORTAL, BWH/HMS | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer
Reposted by Eddie Cliff
The ASH25 Lymphoma Roundup Episode is Out - Edward Cliff
@eddiecliff.bsky.social
oncodaily.com/voices/lymph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@eddiecliff.bsky.social
oncodaily.com/voices/lymph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Edward Cliff: The ASH25 Lymphoma Roundup Episode is Out - OncoDaily
Edward Cliff: The ASH25 Lymphoma Roundup Episode is Out / ASH25, cancer, Eddie Cliff, Edward Cliff, lymphoma, OncoDaily, Oncology
oncodaily.com
January 26, 2026 at 12:50 AM
The ASH25 Lymphoma Roundup Episode is Out - Edward Cliff
@eddiecliff.bsky.social
oncodaily.com/voices/lymph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@eddiecliff.bsky.social
oncodaily.com/voices/lymph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Reposted by Eddie Cliff
For me, this hits close to home. We’ve seen what happened with lomustine and the impact on brain tumor patients when a life-saving therapy becomes inaccessible. These aren’t abstract policy issues — they have real consequences for people.
@eddiecliff.bsky.social @mskcancercenter.bsky.social
@eddiecliff.bsky.social @mskcancercenter.bsky.social
November 21, 2025 at 3:59 PM
For me, this hits close to home. We’ve seen what happened with lomustine and the impact on brain tumor patients when a life-saving therapy becomes inaccessible. These aren’t abstract policy issues — they have real consequences for people.
@eddiecliff.bsky.social @mskcancercenter.bsky.social
@eddiecliff.bsky.social @mskcancercenter.bsky.social
Just out at JNCI, we review 20 years of RCTs in myeloma for lessons in drug development.
Surprisingly, head-to-head trials were as likely to be successful as add-on trials.
academic.oup.com/jnci/advance... #mmsm #myeloma
Surprisingly, head-to-head trials were as likely to be successful as add-on trials.
academic.oup.com/jnci/advance... #mmsm #myeloma
November 9, 2025 at 10:08 PM
Just out at JNCI, we review 20 years of RCTs in myeloma for lessons in drug development.
Surprisingly, head-to-head trials were as likely to be successful as add-on trials.
academic.oup.com/jnci/advance... #mmsm #myeloma
Surprisingly, head-to-head trials were as likely to be successful as add-on trials.
academic.oup.com/jnci/advance... #mmsm #myeloma
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
November 4, 2025 at 9:53 AM
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Reposted by Eddie Cliff
The US Food and Drug Administration accelerated approval pathway spans many nononcologic diseases, especially nonmalignant hematology and neurology, with 25% for infectious disease vaccines.
ja.ma/3Kz6WnV
ja.ma/3Kz6WnV
October 9, 2025 at 12:00 PM
The US Food and Drug Administration accelerated approval pathway spans many nononcologic diseases, especially nonmalignant hematology and neurology, with 25% for infectious disease vaccines.
ja.ma/3Kz6WnV
ja.ma/3Kz6WnV
Reposted by Eddie Cliff
RW pola outcomes by Hans COO @eddiecliff.bsky.social
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
October 27, 2025 at 4:30 PM
RW pola outcomes by Hans COO @eddiecliff.bsky.social
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
Reposted by Eddie Cliff
The urgency is real—but the “Most Favored Nation” drug pricing policy is unlikely to deliver lasting reform. In @jama.com, @eddiecliff.bsky.social and I propose accelerating and strengthening Medicare drug price negotiation to align prices with value.
🔗 jamanetwork.com/journals/jam...
🔗 jamanetwork.com/journals/jam...
August 2, 2025 at 2:01 PM
The urgency is real—but the “Most Favored Nation” drug pricing policy is unlikely to deliver lasting reform. In @jama.com, @eddiecliff.bsky.social and I propose accelerating and strengthening Medicare drug price negotiation to align prices with value.
🔗 jamanetwork.com/journals/jam...
🔗 jamanetwork.com/journals/jam...
Reposted by Eddie Cliff
Viewpoint: The reintroduction of the most favored nation pricing policy aims to curb high US drug prices but faces legal and operational challenges.
ja.ma/4lXJcYs
ja.ma/4lXJcYs
July 28, 2025 at 4:18 PM
Viewpoint: The reintroduction of the most favored nation pricing policy aims to curb high US drug prices but faces legal and operational challenges.
ja.ma/4lXJcYs
ja.ma/4lXJcYs
Just out @jama.com, led by Ian Liu we review 10 years of nononcology accelerated approvals
12/50 vaccines
10 nonmalignant haem
11 neurology
5 nonvaccine ID
>60% conversions to regular approval based on surrogate endpoints
jamanetwork.com/journals/jam... @portalresearch.org @akesselheim.bsky.social
12/50 vaccines
10 nonmalignant haem
11 neurology
5 nonvaccine ID
>60% conversions to regular approval based on surrogate endpoints
jamanetwork.com/journals/jam... @portalresearch.org @akesselheim.bsky.social
July 15, 2025 at 1:05 AM
Just out @jama.com, led by Ian Liu we review 10 years of nononcology accelerated approvals
12/50 vaccines
10 nonmalignant haem
11 neurology
5 nonvaccine ID
>60% conversions to regular approval based on surrogate endpoints
jamanetwork.com/journals/jam... @portalresearch.org @akesselheim.bsky.social
12/50 vaccines
10 nonmalignant haem
11 neurology
5 nonvaccine ID
>60% conversions to regular approval based on surrogate endpoints
jamanetwork.com/journals/jam... @portalresearch.org @akesselheim.bsky.social
Reposted by Eddie Cliff
The US FDA accelerated approval pathway spans many nononcologic diseases, especially nonmalignant hematology and neurology, with 25% for infectious disease vaccines.
https://ja.ma/4lRpuge
https://ja.ma/4lRpuge
July 14, 2025 at 3:45 PM
The US FDA accelerated approval pathway spans many nononcologic diseases, especially nonmalignant hematology and neurology, with 25% for infectious disease vaccines.
https://ja.ma/4lRpuge
https://ja.ma/4lRpuge
Reposted by Eddie Cliff
Currently at #EHA2025: @broeckelmann.bsky.social presenting our recent @thelancethaem.bsky.social commission on adverse events, starting with our paper (with @biostatgirl.bsky.social) on advancing the measurement & dissemination of AE data HT @eddiecliff.bsky.social #EHA25
June 13, 2025 at 1:36 PM
Currently at #EHA2025: @broeckelmann.bsky.social presenting our recent @thelancethaem.bsky.social commission on adverse events, starting with our paper (with @biostatgirl.bsky.social) on advancing the measurement & dissemination of AE data HT @eddiecliff.bsky.social #EHA25
Reposted by Eddie Cliff
🔍Presenting at #ASCO25 as a #poster and now LIVE on our website
Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study
Read the whole paper here: www.thelancet.com/journals/ecl...
#TheLancet #Oncology #OncologyResearch #MedSky
Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study
Read the whole paper here: www.thelancet.com/journals/ecl...
#TheLancet #Oncology #OncologyResearch #MedSky
June 2, 2025 at 2:47 PM
🔍Presenting at #ASCO25 as a #poster and now LIVE on our website
Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study
Read the whole paper here: www.thelancet.com/journals/ecl...
#TheLancet #Oncology #OncologyResearch #MedSky
Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study
Read the whole paper here: www.thelancet.com/journals/ecl...
#TheLancet #Oncology #OncologyResearch #MedSky
Reposted by Eddie Cliff
Announcing the 1st paper of @thelancethaem.bsky.social Commission on Adverse Events, with Drs. @biostatgirl.bsky.social & Thanarajasingam.
We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination.
buff.ly/SchRHhq
Thread ⬇️🧵
We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination.
buff.ly/SchRHhq
Thread ⬇️🧵
May 29, 2025 at 5:45 PM
Announcing the 1st paper of @thelancethaem.bsky.social Commission on Adverse Events, with Drs. @biostatgirl.bsky.social & Thanarajasingam.
We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination.
buff.ly/SchRHhq
Thread ⬇️🧵
We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination.
buff.ly/SchRHhq
Thread ⬇️🧵
What steps can trialists, regulators, journals, editors, reviewers, sponsors & academics take to improve toxicity reporting & identification?
👇 check out this figure from our @thelancethaem.bsky.social adverse event commission
www.thelancet.com/journals/lan... @broeckelmann.bsky.social
👇 check out this figure from our @thelancethaem.bsky.social adverse event commission
www.thelancet.com/journals/lan... @broeckelmann.bsky.social
May 31, 2025 at 11:15 AM
What steps can trialists, regulators, journals, editors, reviewers, sponsors & academics take to improve toxicity reporting & identification?
👇 check out this figure from our @thelancethaem.bsky.social adverse event commission
www.thelancet.com/journals/lan... @broeckelmann.bsky.social
👇 check out this figure from our @thelancethaem.bsky.social adverse event commission
www.thelancet.com/journals/lan... @broeckelmann.bsky.social
Reposted by Eddie Cliff
For the third (open access) paper, I was humbled to coordinate an international author panel to comprehensively summarize challenges, lessons learned and outline future strategies for tolerability assessment with novel, targeted therapeutic approaches: doi.org/10.1016/S235...
May 30, 2025 at 10:30 AM
For the third (open access) paper, I was humbled to coordinate an international author panel to comprehensively summarize challenges, lessons learned and outline future strategies for tolerability assessment with novel, targeted therapeutic approaches: doi.org/10.1016/S235...
The latest in a trio of meta-analyses by Tobias, David & Kai just out at Molecular Therapy, on non-relapse mortality after bispecific antibodies in lymphoma & myeloma.
>70% of non-relapse deaths are due to infection.
Need to prioritise measurement, reporting, prophylaxis, early intervention.
>70% of non-relapse deaths are due to infection.
Need to prioritise measurement, reporting, prophylaxis, early intervention.
April 13, 2025 at 12:27 AM
The latest in a trio of meta-analyses by Tobias, David & Kai just out at Molecular Therapy, on non-relapse mortality after bispecific antibodies in lymphoma & myeloma.
>70% of non-relapse deaths are due to infection.
Need to prioritise measurement, reporting, prophylaxis, early intervention.
>70% of non-relapse deaths are due to infection.
Need to prioritise measurement, reporting, prophylaxis, early intervention.
Just out @jama.com
Led by Dr Hwang we show when oncology drugs withdrawn due to negative trials are still accessible off-abel, prescribing plummets anyway
Romidepsin a notable exception, unsurprising to lymphoma docs who use it in TFH lymphomas
jamanetwork.com/journals/jam... @portalresearch.org
Led by Dr Hwang we show when oncology drugs withdrawn due to negative trials are still accessible off-abel, prescribing plummets anyway
Romidepsin a notable exception, unsurprising to lymphoma docs who use it in TFH lymphomas
jamanetwork.com/journals/jam... @portalresearch.org
April 6, 2025 at 9:34 AM
Just out @jama.com
Led by Dr Hwang we show when oncology drugs withdrawn due to negative trials are still accessible off-abel, prescribing plummets anyway
Romidepsin a notable exception, unsurprising to lymphoma docs who use it in TFH lymphomas
jamanetwork.com/journals/jam... @portalresearch.org
Led by Dr Hwang we show when oncology drugs withdrawn due to negative trials are still accessible off-abel, prescribing plummets anyway
Romidepsin a notable exception, unsurprising to lymphoma docs who use it in TFH lymphomas
jamanetwork.com/journals/jam... @portalresearch.org
Delighted Piers Blombery joined us to discuss CAR transgenic T-cell lymphoproliferative neoplasms & all things post-CAR-T malignancies on Blood Cancer Talks, with a side helping of molecular haematology. We discuss Piers' recent NEJM paper plus recent MSKCC case w transgene integration into TP53.
March 26, 2025 at 10:02 PM
Delighted Piers Blombery joined us to discuss CAR transgenic T-cell lymphoproliferative neoplasms & all things post-CAR-T malignancies on Blood Cancer Talks, with a side helping of molecular haematology. We discuss Piers' recent NEJM paper plus recent MSKCC case w transgene integration into TP53.
A real honour to have Dr Hagop Kantarjian, M.D. on the podcast to talk all things CML, including the recent ASCEMBL trial - a really enjoyable hour packed full of wisdom!
podcasts.apple.com/us/podcast/b...
Check out Blood Cancer Talks on your favourite podcast platform. #leusm #leukemia #cml
podcasts.apple.com/us/podcast/b...
Check out Blood Cancer Talks on your favourite podcast platform. #leusm #leukemia #cml
Blood Cancer Talks
Education Podcast · 57 Episodes · Updated Semimonthly
podcasts.apple.com
February 16, 2025 at 8:55 PM
A real honour to have Dr Hagop Kantarjian, M.D. on the podcast to talk all things CML, including the recent ASCEMBL trial - a really enjoyable hour packed full of wisdom!
podcasts.apple.com/us/podcast/b...
Check out Blood Cancer Talks on your favourite podcast platform. #leusm #leukemia #cml
podcasts.apple.com/us/podcast/b...
Check out Blood Cancer Talks on your favourite podcast platform. #leusm #leukemia #cml
Helpful review on ctDNA in aggressive B-cell lymphomas just out in @jama.com oncology jamanetwork.com/journals/jam... #lymsm #lymphoma
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma
This narrative review explores how the identification of measurable residual disease through methods of detecting circulating tumor DNA contributes to outcomes for B-cell lymphomas.
jamanetwork.com
February 16, 2025 at 5:48 AM
Helpful review on ctDNA in aggressive B-cell lymphomas just out in @jama.com oncology jamanetwork.com/journals/jam... #lymsm #lymphoma
Enticing data for axi-cel in high risk upfront DLBCL in ZUMA-12 3 year followup @BloodJournal
75% 3-year progression free survival
ashpublications.org/blood/articl...
Randomised ZUMA-23 data eagerly awaited
#lymsm #lymphoma
75% 3-year progression free survival
ashpublications.org/blood/articl...
Randomised ZUMA-23 data eagerly awaited
#lymsm #lymphoma
February 15, 2025 at 5:35 AM
Enticing data for axi-cel in high risk upfront DLBCL in ZUMA-12 3 year followup @BloodJournal
75% 3-year progression free survival
ashpublications.org/blood/articl...
Randomised ZUMA-23 data eagerly awaited
#lymsm #lymphoma
75% 3-year progression free survival
ashpublications.org/blood/articl...
Randomised ZUMA-23 data eagerly awaited
#lymsm #lymphoma
Disappointing outcomes for CAR T cells in 31 patients with relapsed/refractory Burkitt lymphoma
Tricky disease to treat. Perhaps combo of chemo and bispecific might offer better long term control
ashpublications.org/blood/articl... #lymsm #lymphoma
Tricky disease to treat. Perhaps combo of chemo and bispecific might offer better long term control
ashpublications.org/blood/articl... #lymsm #lymphoma
Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma
Key Points. Despite having relatively favorable disease kinetics, patients with relapsed/refractory BL who receive CAR T-cells have poor outcomes.Future tr
ashpublications.org
February 15, 2025 at 5:13 AM
Disappointing outcomes for CAR T cells in 31 patients with relapsed/refractory Burkitt lymphoma
Tricky disease to treat. Perhaps combo of chemo and bispecific might offer better long term control
ashpublications.org/blood/articl... #lymsm #lymphoma
Tricky disease to treat. Perhaps combo of chemo and bispecific might offer better long term control
ashpublications.org/blood/articl... #lymsm #lymphoma
SYMPATICO trial - RCT of venetoclax + ibrutinib vs ibr+placebo in R/R mantle cell lymphoma just out in Lancet Oncology
www.sciencedirect.com/science/arti... #lymphoma #lymsm
www.sciencedirect.com/science/arti... #lymphoma #lymsm
February 11, 2025 at 1:10 AM
SYMPATICO trial - RCT of venetoclax + ibrutinib vs ibr+placebo in R/R mantle cell lymphoma just out in Lancet Oncology
www.sciencedirect.com/science/arti... #lymphoma #lymsm
www.sciencedirect.com/science/arti... #lymphoma #lymsm
Updated European guideline on Burkitt lymphoma just out in Lancet Haem - www.thelancet.com/journals/lan... #lymsm #lymphoma #burkitt
Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet
Burkitt lymphoma is a rare lymphoma entity that represents less than 5% of adult lymphomas.
Although prognosis has improved with dose-dense therapy, Burkitt lymphoma remains
an area of clinical and bi...
www.thelancet.com
February 11, 2025 at 12:58 AM
Updated European guideline on Burkitt lymphoma just out in Lancet Haem - www.thelancet.com/journals/lan... #lymsm #lymphoma #burkitt